KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Income towards Parent Company rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Jazz Pharmaceuticals' Income towards Parent Company amounted to $251.5 million in Q3 2025, which was up 373.29% from -$92.0 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Income towards Parent Company peaked at $251.5 million during Q3 2025, and registered a low of -$364.7 million during Q2 2021.
  • Over the past 3 years, Jazz Pharmaceuticals' median Income towards Parent Company value was $126.4 million (recorded in 2023), while the average stood at $113.9 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Income towards Parent Company tumbled by 641.83% in 2022 and then spiked by 1,116.53% in 2023.
  • Jazz Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$32.3 million in 2021, then tumbled by 641.83% to -$240.0 million in 2022, then surged by 139.43% to $94.6 million in 2023, then spiked by 102.01% to $191.1 million in 2024, then climbed by 16.77% to $251.5 million in 2025.
  • Its Income towards Parent Company stands at $251.5 million for Q3 2025, versus -$92.0 million for Q2 2025 and $191.1 million for Q4 2024.